



Notice Concerning Filing of Motion by NTK to Expand Claims in Lawsuit for Compensation for Damages Against Daiichi Sankyo

Tokyo, Japan (May 22, 2025) – As previously announced in the press release dated November 22, 2023*, titled “Daiichi Sankyo’s Statement Regarding NTK’s Complaint,” Northern TK Venture Pte. Ltd. (Headquarters: Singapore; “NTK”), an indirect wholly-owned subsidiary of IHH Healthcare Berhad (Headquarters: Malaysia; “IHH”), filed a lawsuit against Daiichi Sankyo Company, Limited (Headquarters: Chuo-ku, Tokyo; “Daiichi Sankyo”) before the Tokyo District Court in Japan on October 16, 2023, seeking JPY20 billion in damages (“Lawsuit”) among other claims, and the complaint was served on Daiichi Sankyo on November 13, 2023.

Afterwards, in the course of the Lawsuit, NTK filed a “Motion to Amend the Claim” filed on May 9, 2025, in order to expand the amount of damages alleged against Daiichi Sankyo. Daiichi Sankyo therefore announces as follows.

*https://www.daiichisankyo.com/files/news/pressrelease/pdf/202311/20231122_E.pdf

1. Court and Date Lawsuit Was Filed
 - (1) Court where the lawsuit was filed: Tokyo District Court
 - (2) Date of the filing: October 16, 2023 (date of the service of the complaint: November 13, 2023)
 - (3) Date of the filing of the motion to amend the claim: May 9, 2025 (date of the service of the motion to amend: May 20, 2025)
2. Overview of Plaintiff

Name: Northern TK Venture Pte. Ltd.
Location: 1, HARBOURFRONT PLACE, #03-02, HARBOURFRONT TOWER ONE, Singapore 098633
Name and title of representative: Agarwal Aanchal, Representative Director
3. Cause of Lawsuit and Background of Filing of Lawsuit

Daiichi Sankyo has been taking steps for executing an arbitration award against the former shareholders of Ranbaxy dated April 29, 2016, before the courts in India entirely in accordance with Indian law. In the course of these proceedings, NTK’s open offer in respect of Fortis Healthcare Limited (“FHL”) shares was suspended pursuant to the direction of the Supreme Court of India and following due process.

Under these circumstances, NTK filed the Lawsuit alleging that the suspension of the open offer constitutes interference of the open offer by Daiichi Sankyo.

4. Details of Lawsuit

(1) Details of claims

- (i) Claim for damages;
- (ii) Request for an injunction against interference with the open offer; and
- (iii) Demand that a statement prepared by NTK be posted on Daiichi Sankyo's website and that a document containing the same statement be submitted to the Securities and Exchange Board of India (SEBI).

(2) Amount of claim

JPY203,301,807,840

5. Daiichi Sankyo's Positions and Approach

In the Lawsuit, NTK alleges that, among other things, Daiichi Sankyo interfered with NTK's open offer in connection with NTK's acquisition of FHL's shares in India; however, as mentioned in Section 3. above, Daiichi Sankyo has been taking steps for executing an arbitration award dated April 29, 2016, issued in its favor, before the courts in India entirely in accordance with Indian law. The suspension of the open offer in respect of FHL shares was directed by the Supreme Court of India following due process. Subsequently FHL and IHH/NTK filed various applications before the Supreme Court of India and SEBI in India in order to proceed with the open offer, but the relevant permission was not granted.

Therefore, Daiichi Sankyo believes that NTK's claims are without any merit or substance and that the claims are not sustainable. Daiichi Sankyo will continue to defend its position in court.

In the event that any matters call for disclosure going forward such as developments of the Lawsuit, Daiichi Sankyo will issue notifications swiftly.

About Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.

Media Contacts:

Japan:

Daiichi Sankyo Co., Ltd.

DS-PR_jp@daiichisankyo.com

Investor Relations Contact:

DaiichiSankyoIR_jp@daiichisankyo.com